News
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
Vifor Pharma announces changes to the Executive Committee as CFO retires
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021
VAT Medienmitteilung zum Lagebericht 1. Quartal 2022
Dufry Publishes Invitation to its Ordinary General Meeting on May 17, 2022
Einladung: Straumann Group Webcast - Umsatzzahlen 1. Quartal 2022
Invitation: Straumann Group 2022 first-quarter sales webcast
Annual general meeting approves all proposals of the Board of Directors
Generalversammlung genehmigt alle Anträge des Verwaltungsrats
Cyberattack on parts of the Baloise Group's IT infrastructure
Cyberangriff auf Teile der IT-Infrastruktur der Baloise Gruppe
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
22. ordentliche Generalversammlung der Luzerner Kantonalbank AG Beschlüsse der LUKB-Generalversammlung vom 11. April 2022
Einladung zum Konferenz Call zum Lagebericht des 1. Quartals 2022
Quartalsabschluss der Luzerner Kantonalbank AG per 31. März 2022
Baloise teilt ihr Know-how mit Gründerinnen und Gründern
Baloise shares its know-how with start-up founders